Drugs & Therapy Perspectives (2023) 39:248
https://doi.org/10.1007/s40267-023-01002-3

DRUG REACTIONS AND INTERACTIONS

First reports of adverse drug reactions

Accepted: 18 May 2023 / Published online: 15 June 2023

Table 1 contains an overview of first published case reports of adverse drug reactions identified in the international literature in recent weeks by *Reactions Weekly*, the Adis drug safety newsletter. *Reactions Weekly* provides summaries of adverse drug reaction news sourced from journals, scientific meetings, media releases, regulatory agency websites, and bulletins from the National Centers that participate in the WHO International Drug Monitoring Programme.

Table 1 First reports of adverse drug reactions

Drug: event	References
Camrelizumab: dermatomyositis (serious)	Li J, et al. Anti-TIF1-gamma antibody-positive dermatomyositis caused by camrelizumab in a patient with oesophageal cancer. Clin Exp Rheumatol. 2023;41(2):395
Elexacaftor/ivacaftor/tezacaftor: eruptive melanocytic naevi	Atkinson M, et al. Eruptive melanocytic naevi following initiation of elexacaftor/ivacaftor/tezacaftor for cystic fibrosis. J Cyst Fibros 2022;21(6):1070–1073
Sacubitril + valsartan: Raynaud's phenomenon	Dass P, et al. Sacubitril-induced Raynaud's phenomenon: first report in literaturetes. Int J Rheum Dis 2023;26(1): 130–1
Tislelizumab: enteritis (serious)	Chen N, et al. Tislelizumab-related enteritis successfully treated with adalimumab: A case report. World J Clin Cases. 2022;10(28):10186–92
Trazodone: hypogeusia	Tekdemir R, et al. A case of trazodone induced prolonged hypogeusia. Eur Psychiatry 65(Suppl 1): S719–S720

An event is serious (US FDA MedWatch definition) when the patient outcome is death, life threatening, hospitalization, disability, congenital anomaly or requires intervention to prevent permanent impairment or damage